Astera Labs, Inc. $ALAB Shares Sold by Peregrine Investment Management Inc.

Peregrine Investment Management Inc. lessened its holdings in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 33.5% during the third quarter, HoldingsChannel reports. The fund owned 97,070 shares of the company’s stock after selling 48,970 shares during the period. Astera Labs comprises approximately 9.3% of Peregrine Investment Management Inc.’s investment portfolio, making the stock its biggest holding. Peregrine Investment Management Inc.’s holdings in Astera Labs were worth $19,006,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Assetmark Inc. boosted its position in shares of Astera Labs by 374.1% during the 3rd quarter. Assetmark Inc. now owns 128 shares of the company’s stock worth $25,000 after purchasing an additional 101 shares in the last quarter. Clearstead Trust LLC lifted its stake in shares of Astera Labs by 46,100.0% in the second quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock valued at $42,000 after purchasing an additional 461 shares during the period. Advisors Asset Management Inc. increased its holdings in Astera Labs by 68.6% in the second quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock valued at $43,000 after buying an additional 194 shares in the last quarter. Manchester Capital Management LLC boosted its stake in shares of Astera Labs by 141.5% during the 2nd quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock worth $44,000 after acquiring an additional 283 shares in the last quarter. Finally, Whittier Trust Co. acquired a new stake in shares of Astera Labs in the 3rd quarter worth approximately $55,000. Institutional investors and hedge funds own 60.47% of the company’s stock.

Insider Transactions at Astera Labs

In other Astera Labs news, COO Sanjay Gajendra sold 90,459 shares of the firm’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $144.69, for a total transaction of $13,088,512.71. Following the transaction, the chief operating officer owned 1,599,750 shares of the company’s stock, valued at approximately $231,467,827.50. This trade represents a 5.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jitendra Mohan sold 90,459 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $144.69, for a total transaction of $13,088,512.71. Following the completion of the sale, the chief executive officer directly owned 2,080,418 shares of the company’s stock, valued at approximately $301,015,680.42. This represents a 4.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 576,936 shares of company stock worth $87,409,540 over the last ninety days. Insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Needham & Company LLC upped their price objective on shares of Astera Labs from $205.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Jefferies Financial Group reissued a “buy” rating on shares of Astera Labs in a research report on Wednesday, December 3rd. Raymond James Financial initiated coverage on Astera Labs in a research note on Friday, November 21st. They issued a “hold” rating for the company. Stifel Nicolaus upped their price objective on Astera Labs from $185.00 to $200.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, Wall Street Zen lowered Astera Labs from a “buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Fourteen research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $192.89.

Key Headlines Impacting Astera Labs

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Q4 beat on revenue and EPS with strong growth and margins — the company reported $270.6M revenue, 75.7% gross margin and an EPS beat, and management issued solid Q1 guidance that underscores hyperscaler demand. ALAB Q4 Earnings Beat (Zacks)
• Positive Sentiment: Wall‑street analysts still see upside tied to large AI infrastructure customers (NVIDIA, AMD, Amazon, Google) and JPMorgan highlighted Astera as a beneficiary of AI buildout. That underpins medium‑term demand expectations. JPMorgan Upside Note (Benzinga)
• Neutral Sentiment: Analysts/transcripts available — full earnings call transcript and Seeking Alpha pieces provide granular color on product ramps (Scorpio X) and margin trajectory; read if you need detail on guidance cadence into H2/2027. Earnings Analysis & Transcript (Seeking Alpha)
• Neutral Sentiment: Reported short‑interest entries appear to be data anomalies (values show 0 and NaN); no actionable evidence of a meaningful short squeeze or buildup from the published figures. Earnings Call Transcript (MSN)
• Negative Sentiment: Investors are booking profits after a massive run-up; several outlets flagged profit‑taking and a “rich” valuation as reasons for the selloff despite the beat. Profit‑Taking After Earnings (Seeking Alpha)
• Negative Sentiment: Concerns about concentration and deal terms: coverage highlighted Amazon’s reported $6.5B engagement as a “double‑edged sword” (big revenue opportunity but customer concentration/contract risk), which weighed on sentiment. Amazon Deal Concerns (MarketWatch)
• Negative Sentiment: CFO change and other corporate developments introduced near‑term uncertainty; several writeups linked management changes to the intra‑day weakness as investors reassessed execution risk. Slide After Earnings, CFO Change (Benzinga)

Astera Labs Stock Down 11.9%

Shares of ALAB stock opened at $126.58 on Friday. The company has a market cap of $21.38 billion, a P/E ratio of 103.75, a PEG ratio of 1.96 and a beta of 1.50. The business has a 50 day moving average of $164.73 and a two-hundred day moving average of $174.08. Astera Labs, Inc. has a 52 week low of $47.13 and a 52 week high of $262.90.

Astera Labs (NASDAQ:ALAB) last announced its quarterly earnings results on Tuesday, February 10th. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.07. The business had revenue of $270.58 million for the quarter, compared to the consensus estimate of $249.46 million. Astera Labs had a return on equity of 16.87% and a net margin of 25.70%.The business’s revenue was up 91.8% on a year-over-year basis. During the same quarter last year, the business posted $0.37 EPS. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. Analysts expect that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Astera Labs Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.